Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

N/A

4(44.4%)

Phase 2

3(33.3%)

Phase 3

2(22.2%)

9Total

N/A(4)

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06601621Not ApplicableRecruiting

Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy

Role: lead

NCT06952920Phase 3Recruiting

Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer

Role: lead

NCT06200168Phase 3Recruiting

Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer

Role: lead

NCT06642428Not ApplicableRecruiting

Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer

Role: lead

NCT06642441Not ApplicableRecruiting

Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer

Role: lead

NCT04722718Phase 2Unknown

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Role: lead

NCT05216237Phase 2Unknown

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

Role: lead

NCT04774497Not ApplicableUnknown

Effect of Oxygen Inhalation on Fatigue After Chemotherapy of Breast Cancer in High Altitude Area

Role: lead

NCT04767620Phase 2Unknown

Clinical Trial of Ruxian Zengsheng No. 1 Decoction

Role: lead

All 9 trials loaded